Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kestra Medical Technologies (KMTS) Gains from Investment Securities (2024 - 2026)

Kestra Medical Technologies (KMTS) has disclosed Gains from Investment Securities for 2 consecutive years, with $2.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Gains from Investment Securities rose 145.93% to $2.3 million in Q4 2025 year-over-year; TTM through Oct 2025 was $2.3 million, a 145.93% increase, with the full-year FY2025 number at $4.6 million, up 46391.0% from a year prior.
  • Gains from Investment Securities was $2.3 million for Q4 2025 at Kestra Medical Technologies, up from $109800.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $4.6 million in Q2 2025 to a low of -$255000.0 in Q3 2024.